ARO-APOC3是Arrowhead开发的一种RNA干扰（RNAi）治疗，在健康受试者中给与单次剂量后可以抑制肝细胞APOC的mRNA。 旨在通过降低APOC3蛋白的表达水平，从而在降低TG和VLDL水平的同时，提升HDL水平。

2023年8月25日 · Animal studies show that ARO-ANG3 is highly effective in inhibiting both the ANGPTL3 mRNA transcript and the hepatic production of the ANGPTL3 protein, with corresponding reductions in TG, LDL-C...

2023年8月30日 · ARO-ANG3 是 Arrowhead 公司公司开发的皮下给药的siRNA药物，通过靶向肝脏细胞，抑制细胞质中的ANGPTL3的mRNA。 之前的动物实验表明，ARO-ANG3可高效抑制肝脏中ANGPTL3 mRNA转录和ANGPTL3蛋白生成，并相应降低 甘油三酯 （TG）、 低密度脂蛋白胆固醇 （LDL-C）和 高密度脂蛋白胆固醇 （HDL-C）。 在人类中，这种效果可能降低 动脉粥样硬化性心血管疾病 （ASCVD）风险，特别是对于缺乏足够低密度脂蛋白受体（LDLR）的患者（ …

2023年11月6日 · ANGPTL3 loss-of-function carriers have decreased circulating triglycerides (TGs), LDL-C, and HDL-C, and a lower risk of atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an investigational RNAi therapeutic designed to inhibit hepatic ANGPTL3 expression and reduce atherogenic lipoproteins.

2023年8月28日 · ARO-ANG3是一款通过皮下注射、靶向血管生成素样蛋白3（ANGPTL3）mRNA的RNAi疗法，ANGPTL3是一种由肝脏分泌产生的代谢调节因子，是调控血清脂质和脂蛋白 ...

ARO-ANG3 is an investigational, hepatocyte-targeted RNA interference (RNAi) therapeutic designed to specifically silence ANGPTL3 mRNA expression and mimic ANGPTL3 deficiency

2024年5月29日 · Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants.

ARO-ANG3 is an RNA interference therapy that targets angiopoietin-like protein 3 (ANGPTL3), a regulator of lipoprotein metabolism. This first-in-human, phase 1, randomized, placebo-controlled, open-label trial investigated single and repeat ARO-ANG3 doses in four cohorts of fifty-two healthy participants and one cohort of nine participants with ...

ARO-ANG3 is a synthetic, double-stranded, hepatocyte-targeted NAG-conjugated RNAi trigger designed to target mRNA transcripts from the ANGPTL3 gene using an RNAi mechanism, thereby...

Zodasiran, previously called ARO-ANG33, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of angiopoietin-like protein (ANGPTL3), which is a hepatocyte expressed regulator of lipid and lipoprotein metabolism with multiple potential modes of action, including inhibition of lipoprotein lipase ...